Ankerstar Wealth’s Pacira BioSciences PCRX Stock Holding History

Ankerstar Wealth’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304	Hold	12	–	–	﹤0.01%	795
2026 Q1	$271	Buy	12 +7	+140%	+$156	﹤0.01%	787
2025 Q4	$129	Buy	+5	New	+$119	﹤0.01%	972

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ankerstar Wealth's PCRX Position: Q2 2026 in Review

Ankerstar Wealth held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 12 shares worth $304. The position accounts for ﹤0.01% of the portfolio, ranked #795.

Ankerstar Wealth first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Ankerstar Wealth held 12 shares of Pacira BioSciences worth $304 as of Q2 2026.
Ankerstar Wealth left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #795 holding.
Ankerstar Wealth first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.